| Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526) |
|---|
| 01/05/2012 | WO2011033322A3 Crystal structure |
| 01/05/2012 | WO2002092832A9 Human and non-human primate homologues of nkd protein, nucleic acid sequences encoding, and uses thereof |
| 01/05/2012 | WO2002026936A9 Gene expression in the central nervous system regulated by neuroleptic agents |
| 01/05/2012 | US20120005790 Analogs of temporin-sha and uses thereof |
| 01/05/2012 | US20120005786 Isolated Polynucleotide Molecules Corresponding to Mutant and Wild-Type Alleles of the Maize D9 Gene and Methods of Use |
| 01/05/2012 | US20120005783 Ice recrystallisation inhibition protein or antifreeze proteins from deschampsia, and festuca species of grass |
| 01/05/2012 | US20120005768 Circovirus Sequences Associated With Piglet Weight Loss Disease (PWD) |
| 01/05/2012 | US20120005767 Antibodies to insulin-like growth factor i receptor |
| 01/05/2012 | US20120004402 Crh and pomc effects on animal growth |
| 01/05/2012 | US20120004397 Violet laser excitable dyes and their method of use |
| 01/05/2012 | US20120004396 Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
| 01/05/2012 | US20120004395 Use Of Serine Protease Inhibitors In The Treatment Of Neutropenia |
| 01/05/2012 | US20120004394 Immunosuppressive peptide |
| 01/05/2012 | US20120004392 Selective glucagon-like-peptide-2 (glp-2) analogues |
| 01/05/2012 | US20120004391 Cyanine-type compounds having an alkynyl linker arm |
| 01/05/2012 | US20120004186 Platelet aggregation inhibitor composition |
| 01/05/2012 | US20120004185 Polypeptide structural motifs associated with cell signaling activity |
| 01/05/2012 | US20120004183 Unnatural reactive amino acid genetic code additions |
| 01/05/2012 | US20120004181 Targeted delivery system |
| 01/05/2012 | US20120004179 Means and methods for manufacturing highly pure neurotoxin |
| 01/05/2012 | US20120004178 Biglycan mutants and related therapeutics and methods of use |
| 01/05/2012 | US20120004172 Screening method of anti-lung or esophageal cancer compounds |
| 01/05/2012 | US20120004171 Novel therapies for chronic renal failure |
| 01/05/2012 | US20120004170 Formulation Comprising Bioactive Agents And Method Of Using Same |
| 01/05/2012 | US20120004168 Exendins and exendin agonist analogs to regulate gastrointestinal motility |
| 01/05/2012 | US20120004161 Homogenous preparations of il-28 and il-29 |
| 01/05/2012 | US20120003713 Polymerase Enhancing Factor (PEF) Extracts PEF Protein Complexes Isolated PEF Proteins and Methods for Purifying and Identifying |
| 01/05/2012 | US20120003712 Method for preparing a site-specific physiologically active polypeptide conjugate |
| 01/05/2012 | US20120003699 Separtion of tagged fragments |
| 01/05/2012 | US20120003694 Bioengineered Protein Pores |
| 01/05/2012 | US20120003691 Method of isolation and purification of trypsin from pronase protease and use thereof |
| 01/05/2012 | US20120003674 Chloral Hydrate Detection |
| 01/05/2012 | US20120003673 Screening method, composition containing substance selected by the screening method, and binding substance |
| 01/05/2012 | US20120003670 Methods and Kits for Measuring Von Willebrand Factor |
| 01/05/2012 | US20120003269 Compositions Produced Using Enteric Pathogens and Methods of Use |
| 01/05/2012 | US20120003267 Therapeutic Agents |
| 01/05/2012 | US20120003264 CDNA Corresponding to the Antigenome of Nonsegmented Negative Stranded RNA Viruses and Process for the Production of Such Viruses |
| 01/05/2012 | US20120003259 Molecule |
| 01/05/2012 | US20120003258 Mutant forms of streptolysin o |
| 01/05/2012 | US20120003256 Tuberculosis antigens, immunogenic compositions, diagnostics and methods related to the same |
| 01/05/2012 | US20120003255 Flavivirus host-range mutations and uses thereof |
| 01/05/2012 | US20120003252 Isoforms of human somatostatin receptor type 5 produced by alternative processing and oligo-nucleotide pairs for detection thereof by pcr |
| 01/05/2012 | US20120003249 Immuno-molecules containing viral proteins, compositions thereof and methods of using |
| 01/05/2012 | US20120003246 Novel composition and methods for the treatment of psoriasis |
| 01/05/2012 | US20120003243 Yeast ectopically expressing abnormally processed proteins and uses therefor |
| 01/05/2012 | US20120003231 Cell surface molecule mediating cell adhesion and signal transmission |
| 01/05/2012 | US20120003222 Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules and treatments using same |
| 01/05/2012 | US20120003216 Fgf21 mutants and uses thereof |
| 01/05/2012 | US20120003214 Binding Moieties Based On Shark IgNAR Domains |
| 01/05/2012 | US20120003203 Compositions and Methods for Treating S. Pneumoniae Infection |
| 01/05/2012 | US20120003181 Novel Retinoid Inducible Factor and Uses Thereof |
| 01/05/2012 | US20120003119 Antimicrobial peptides |
| 01/05/2012 | DE112008001837T5 Pflanzen mit verbesserten Ertragsmerkmalen und Verfahren zu ihrer Herstellung Plants having enhanced yield characteristics and methods for their preparation |
| 01/05/2012 | DE102010025935A1 Collagen with specified proline to hydroxyproline ratio and glycosylation degree as measured by the ratio of disaccharides to monosaccharides, useful as wound gel for treating wounds, and for tissue engineering |
| 01/05/2012 | CA2803989A1 Env trimer immunogens |
| 01/05/2012 | CA2803986A1 Polypeptide having or assisting in carbohydrate material degrading activity and uses thereof |
| 01/05/2012 | CA2803982A1 Polypeptide having beta-glucosidase activity and uses thereof |
| 01/05/2012 | CA2803723A1 Gene involved in the development of the seed |
| 01/05/2012 | CA2803646A1 Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof |
| 01/05/2012 | CA2803298A1 Compositions and methods related to protein a (spa) variants |
| 01/05/2012 | CA2803234A1 Histone citrullinated peptides and uses thereof |
| 01/05/2012 | CA2802896A1 Methods for culturing undifferentiated cells using sustained release compositions |
| 01/05/2012 | CA2802128A1 Polypeptide having beta-glucosidase activity and uses thereof |
| 01/05/2012 | CA2801824A1 Polypeptide having swollenin activity and uses thereof |
| 01/04/2012 | EP2402459A2 Genes involved in Asymmetric Cell Division |
| 01/04/2012 | EP2402450A1 Methods to obtain recombinant proteins with decreased LacdiNac structures |
| 01/04/2012 | EP2402447A1 Endogenous retrovirus and proteins encoded by env gene as a target for cancer treatment |
| 01/04/2012 | EP2402446A1 Gene involved in the development of the seed |
| 01/04/2012 | EP2402445A1 Recombinant vaccines against caligid copepods (sea lice) and antigen sequences thereof |
| 01/04/2012 | EP2402444A1 Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| 01/04/2012 | EP2402435A2 Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy |
| 01/04/2012 | EP2402369A2 Peptide fragments for inducing synthesis of extracellular matrix proteins |
| 01/04/2012 | EP2402368A1 Histone citrullinated peptides and uses thereof |
| 01/04/2012 | EP2402367A1 Library from toxin mutants, and methods of using same |
| 01/04/2012 | EP2402366A1 Antibiotic 107891, its factors a1 and a2, pharmaceutically acceptable salts and compositions, und use thereof |
| 01/04/2012 | EP2402365A1 Crystal structure of amino terminal portion of influenza virus polymerase pa subunit and use thereof |
| 01/04/2012 | EP2402359A1 Recombinant protective protein from streptococcus pneumoniae |
| 01/04/2012 | EP2402029A1 Enterovirus vaccines for preventing or treating type 1 diabetes (III) |
| 01/04/2012 | EP2402028A1 Enterovirus vaccines for preventing and treating type 1 diabetes (II) |
| 01/04/2012 | EP2402027A1 Enterovirus vaccines for preventing or treating type 1 diabetes (I) |
| 01/04/2012 | EP2402026A2 Method for isolating hepatitis C virus peptides |
| 01/04/2012 | EP2401920A1 Method for the production of maize proteins and use of said proteins for the production of gluten-free bakery products and pasta |
| 01/04/2012 | EP2401380A2 Pesticidal proteins and methods for their use |
| 01/04/2012 | EP2401302A1 Antibodies containing therapeutic tpo/epo mimetic peptides |
| 01/04/2012 | EP2401301A2 Apparatus, system, and method for creating immunologically enhanced spaces in-vivo |
| 01/04/2012 | EP2401293A2 Designer ligands of tgf-beta superfamily |
| 01/04/2012 | EP2401292A1 Antibodies to troponin i and methods of use thereof |
| 01/04/2012 | EP2401291A1 Plants having enhanced yield-related traits and a method for making the same |
| 01/04/2012 | EP2401290A1 Cellobiose dehydrogenase |
| 01/04/2012 | EP2401289A1 Alteration and modulation of protein activity by varying post-translational modification |
| 01/04/2012 | EP2175877B1 Use of mutated antithrombins for treating or preventing coagulation disorders |
| 01/04/2012 | EP2046822B1 Molecular probe for sphingolipids |
| 01/04/2012 | EP1919932B1 Prion inactivation |
| 01/04/2012 | EP1624847B1 Compositions and methods for the preparation of human growth hormone glycosylation mutants |
| 01/04/2012 | EP1187850B1 Antimicrobial theta defensins and methods of using same |
| 01/04/2012 | EP1080107B1 Novel peptides which represent the epitopes of the human herpes virus type 8 |
| 01/04/2012 | EP0914142B9 Peptides with increased binding affinity for at least three hla-a3-like molecules |
| 01/04/2012 | CN1944460B Alr polypeptide and application thereof |
| 01/04/2012 | CN1839154B Isoforms of elF-5A: senescence-induced elF-5A, wounding-induced elF-5A, growth elF-5A, and DHS |
| 01/04/2012 | CN1798838B Inhibitor proteins of a protease and use thereof |